sb 203580 has been researched along with Libman-Sacks Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, H; Jiang, D; Jin, N; Wang, Q; Zhang, X; Zhu, K | 1 |
| Qiao-Ling, Z; Rong, T; Xiao-xia, Z; Xiao-Zhao, L; Zhi-Chun, L; Zhi-Qin, L | 1 |
2 other study(ies) available for sb 203580 and Libman-Sacks Disease
| Article | Year |
|---|---|
The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Complement C3; Creatinine; Female; Hepatocytes; Imidazoles; Immunoglobulins; Kidney; Kidney Diseases; Liver; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Proteinuria; Pyridines; Spleen | 2011 |
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Cells, Cultured; Chemokine CCL2; Female; Humans; Imidazoles; Interleukin-10; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; MAP Kinase Signaling System; Middle Aged; p38 Mitogen-Activated Protein Kinases; Phytohemagglutinins; Pyridines; Receptors, Tumor Necrosis Factor; Tetradecanoylphorbol Acetate; Tumor Necrosis Factors; TWEAK Receptor; Young Adult | 2012 |